The long non-coding RNA ANRASSF1 in the regulation of alternative protein-coding transcripts RASSF1A and RASSF1C in human breast cancer cells: implications to epigenetic therapy

References

• Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta. 2009 Dec;1796:114–128.
   PubMed Web of Science ®Google Scholar
• Pfeifer GP, Dammann R, Li C, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000 Jul;25:315–319.
   PubMed Web of Science ®Google Scholar
• Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The international lung cancer chromosome 3p21.3 tumor suppressor gene consortium. Cancer Res. 2000 Nov;60:6116–6133.
   PubMed Web of Science ®Google Scholar
• Ji L, Minna JD, Roth JA. 3p21.3 tumor suppressor cluster: prospects for translational applications. Future Oncol. 2005 Feb 1;1:79–92.
   PubMedGoogle Scholar
• Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene. 2007;26:7283–7301.
   PubMed Web of Science ®Google Scholar
• Dammann R, Schagdarsurengin U, Seidel C, et al. The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol. 2005;20:645–663.
   PubMed Web of Science ®Google Scholar
• Volodko N, Gordon M, Salla M, et al. RASSF tumor suppressor gene family: biological functions and regulation. FEBS Lett. 2014;588:2671–2684.
   PubMed Web of Science ®Google Scholar
• Pfeifer GP, Dammann R. Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochem (Mosc). 2005 May;70:576–583.
   PubMed Web of Science ®Google Scholar
• Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci. 2007 Sep;120:3163–3172.
   PubMed Web of Science ®Google Scholar
• Dworkin AM, Huang TH-M, Toland AE. Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol. 2009 Jun;19:165–171.
   PubMed Web of Science ®Google Scholar
• Amaar YG, Minera MG, Hatran LK, et al. Ras association domain family 1C protein stimulates human lung cancer cell proliferation. Am J Physiol Lung Cell Mol Physiol. 2006;291:L1185–L1190.
   PubMed Web of Science ®Google Scholar
• Estrabaud E, Lassot I, Blot G, et al. RASSF1C, an isoform of the tumor suppressor RASSF1A, promotes the accumulation of β-catenin by interacting with βTrCP. Cancer Res. 2007;67:1054–1061.
   PubMed Web of Science ®Google Scholar
• Reeves ME, Baldwin SW, Baldwin ML, et al. Ras-association domain family 1C protein promotes breast cancer cell migration and attenuates apoptosis. BMC Cancer. 2010;Oct;10:562.
   PubMed Web of Science ®Google Scholar
• Reeves ME, Firek M, Chen S-T, et al. The RASSF1 gene and the opposing effects of the RASSF1A and RASSF1C isoforms on cell proliferation and apoptosis. Mol Biol Int. 2013;2013:145096.
   PubMedGoogle Scholar
• da Costa Prando E, Cavalli LR, Rainho C. Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines. Epigenetics. 2011;6:1413–1424.
   PubMed Web of Science ®Google Scholar
• Beckedorff FC, Ayupe AC, Crocci-Souza R, et al. The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation. PLoS Genet. 2013;9:e1003705.
   PubMed Web of Science ®Google Scholar
• Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature. 2011 Jan;469:343–349.
   PubMed Web of Science ®Google Scholar
• Viré E, Brenner C, Deplus R, et al. The polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006;439:871–874.
   PubMed Web of Science ®Google Scholar
• Gu F, Doderer MS, Huang Y-W, et al. CMS: a web-based system for visualization and analysis of genome-wide methylation data of human cancers. Chuang EY, editor. PLoS One. 2013;8:e60980.
   PubMed Web of Science ®Google Scholar
• Díez-Villanueva A, Mallona I, Peinado MA. Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer. Epigenet Chromatin. 2015 Jun;23(8):22.
   Google Scholar
• Grawenda AM, O’Neill E. Clinical utility of RASSF1A methylation in human malignancies. Br J Cancer. 2015 Jul;113:372–381.
   PubMed Web of Science ®Google Scholar
• Xu J, Shetty PB, Feng W, et al. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer. 2012;12:243.
   PubMed Web of Science ®Google Scholar
• Han Z-H, Xu C-S, Han H, et al. Value of the level of methylation of RASSF1A and WIF-1 in tissue and serum in neoadjuvant chemotherapeutic assessment for advanced breast cancer. Oncol Lett. 2017;14:4499–4504.
   PubMed Web of Science ®Google Scholar
• Hagrass HA, Pasha HF, Shaheen MA, et al. Methylation status and protein expression of RASSF1A in breast cancer patients. Mol Biol Rep. 2014;41:57–65.
   PubMed Web of Science ®Google Scholar
• Reis EM, Nakaya HI, Louro R, et al. Antisense intronic non-coding RNA levels correlate to the degree of tumor differentiation in prostate cancer. Oncogene. 2004;23:6684–6692.
   PubMed Web of Science ®Google Scholar
• Iranpour M, Soudyab M, Geranpayeh L, et al. Expression analysis of four long noncoding RNAs in breast cancer. Tumor Biol. 2016;37:2933–2940.
   PubMedGoogle Scholar
• Kangarlouei R, Irani S, Noormohammadi Z, et al. ANRIL and ANRASSF1 long noncoding RNAs are upregulated in gastric cancer. J Cell Biochem. 2019 Mar 4:1–5. Epub ahead of print. DOI: 10.1002/jcb.28520
   Google Scholar
• Rasool M, Malik A, Zahid S, et al. Non-coding RNAs in cancer diagnosis and therapy. Non-Coding RNA Res. 2016;1:69–76.
   PubMedGoogle Scholar
• Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22:1775–1789.
   PubMed Web of Science ®Google Scholar
• Castanotto D, Tommasi S, Li M, et al. Short hairpin RNA-directed cytosine (CpG) methylation of the RASSF1A gene promoter in HeLa cells. Mol Ther. 2005;12:179–183.
   PubMed Web of Science ®Google Scholar
• Mayor R, Muñoz M, Coolen MW, et al. Dynamics of bivalent chromation domains upon drug induced reactivation and resilencing in cancer cells. Epigenetics. 2011;6(9):1138–1148.
   PubMed Web of Science ®Google Scholar
• Djebali S, Davis CA, Merkel A, et al. Landscape of transcription in human cells. Nature. 2012;489:101–108.
   PubMed Web of Science ®Google Scholar
• Malih S, Saidijam M, Malih N. A brief review on long noncoding RNAs: a new paradigm in breast cancer pathogenesis, diagnosis and therapy. Tumor Biol. 2016 Feb;37:1479–1485.
   PubMedGoogle Scholar
• Lavorgna G, Vago R, Sarmini M, et al. Long non-coding RNAs as novel therapeutic targets in cancer. Pharmacol Res. 2016;110:131–138.
   PubMed Web of Science ®Google Scholar
• Slaby O, Laga R, Sedlacek O. Therapeutic targeting of non-coding RNAs in cancer. Biochem J. 2017 Dec;474:4219–4251.
   PubMed Web of Science ®Google Scholar
• Caldeira JRF, Prando EC, Quevedo FC, et al. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer. 2006;6:48.
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Wolff AC, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010 Jul;6:195–197.
   PubMedGoogle Scholar